Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KYMR Kymera Therapeutics, Inc.

盘后交易 10-20 16:29:53 EDT

113.46

+5.39

+4.99%

盘后113.46

+0.000.00%

16:10 EDT

最高115.28	最低108.49	成交量68.90万
今开108.75	昨收108.07	日振幅6.28%
总市值94.34亿	流通市值75.25亿	总股本8,315万
成交额7,777万	换手率1.04%	流通股本6,633万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KYMR","market":"US","secType":"STK","nameCN":"Kymera Therapeutics, Inc.","latestPrice":113.46,"timestamp":1792526400000,"preClose":108.07,"halted":0,"volume":688980,"hourTrading":{"tag":"盘后","latestPrice":113.46,"preClose":113.46,"latestTime":"16:10 EDT","volume":15908,"amount":1804926.13424,"timestamp":1792527005238,"change":0,"changeRate":0,"amplitude":0.040014},"delay":0,"changeRate":0.049875080966040534,"floatShares":66325824,"shares":83150618,"eps":-3.212195,"marketStatus":"盘后交易","change":5.39,"latestTime":"10-20 16:29:53 EDT","open":108.75,"high":115.28,"low":108.49,"amount":77771740,"amplitude":0.06283,"askPrice":120,"askSize":10,"bidPrice":107,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-3.212195,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1792540800000},"marketStatusCode":4,"adr":0,"listingDate":1597982400000,"exchange":"NASDAQ","adjPreClose":108.07,"preHourTrading":{"tag":"盘前","latestPrice":109.25,"preClose":108.07,"latestTime":"09:28 EDT","volume":727,"amount":79561.45508,"timestamp":1792502937891,"change":1.18,"changeRate":0.010919,"amplitude":0.015823},"postHourTrading":{"tag":"盘后","latestPrice":113.46,"preClose":113.46,"latestTime":"16:10 EDT","volume":15908,"amount":1804926.13424,"timestamp":1792527005238,"change":0,"changeRate":0,"amplitude":0.040014},"volumeRatio":0.906101,"impliedVol":1.368,"impliedVolPercentile":0.9323},"requestUrl":"/m/hq/s/KYMR","defaultTab":"news","newsList":[{"id":"1116525716","title":"财报前瞻 ｜Kymera Therapeutics, Inc.本季度营收预计增30.14%，机构观点看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1116525716","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116525716?lang=zh_cn&edition=full","pubTime":"2026-07-30 00:18","pubTimestamp":1785341936,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc.将于2026年08月05日美股盘前发布财报，以下为关键预测与看点。市场一致预期本季度Kymera Therapeutics, Inc.营收为3,043.68万美元，同比增长30.14%，调整后每股收益为-0.72美元，同比改善11.45%；公司在上一季度公开文件中未给出针对本季度的毛利率、净利润或净利率、调整后每股收益等明确指引，相关口径暂无可披露数据。发展前景最大的现有业务仍是“合作”收入，上季度实现3,436.50万美元，同比增长55.50%，为后续季度的业绩可见度提供支撑。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜Kymera Therapeutics, Inc.本季度营收预计增30.14%，机构观点看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176205308","title":"RBC将Kymera Therapeutics评级下调至行业表现，目标价上调至115美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176205308","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176205308?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:33","pubTimestamp":1783935195,"startTime":"0","endTime":"0","summary":"RBC资本市场调整了对Kymera Therapeutics Inc.的投资评级，将其从“跑赢大盘”下调至“行业表现”。与此同时，该机构将其目标股价从106美元上调至115美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151401569","title":"Kymera Therapeutics任命Elizabeth Laws博士为全球项目团队负责人，负责首创口服Stat6降解剂KT-621的研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1151401569","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151401569?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:05","pubTimestamp":1783422350,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics宣布任命Elizabeth Laws博士担任高级副总裁兼全球项目团队负责人，将全面负责公司首创口服Stat6降解剂KT-621的研发项目。此项人事任命旨在加速该创新疗法的临床开发进程。KT-621作为一款具有突破性潜力的候选药物，其研发进展备受业界关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102703936","title":"异动解读｜Kymera Therapeutics盘中下跌7.48%，报107.82美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102703936","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102703936?lang=zh_cn&edition=full","pubTime":"2026-06-27 01:57","pubTimestamp":1782496658,"startTime":"0","endTime":"0","summary":"6月26日，Kymera Therapeutics盘中下跌7.48%，报107.82美元/股，成交额1.24亿美元。Kymera Therapeutics所在的生物科技行业中，个股中，艾伯维公司涨1.5%，福泰制药涨2.65%，Moderna涨12.43%，吉利德科学涨2.39%，Apogee Therapeutics跌0.04%。Kymera Therapeutics是一家临床阶段生物制药公司，专注于利用人体天然蛋白质降解系统开发新型小分子疗法，拥有专有的Pegasus靶向蛋白质降解平台，核心管线KT-621为首创口服STAT6降解剂，目前正推进针对特应性皮炎及哮喘的2b期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128024472","title":"Kymera Therapeutics完成湿疹中期试验入组，盘前股价大涨10.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1128024472","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128024472?lang=zh_cn&edition=full","pubTime":"2026-06-25 19:55","pubTimestamp":1782388515,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics公司宣布，其针对湿疹的中期临床试验已完成患者入组工作。受此消息提振，该公司股价在盘前交易时段大幅上涨10.2%。\n这一进展标志着该公司主要研发项目中的一个重要里程碑，为后续的数据分析和临床结果评估铺平了道路。市场对这项试验的潜在积极成果抱有期待，从而推动了股价的显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190555506","title":"Kymera Therapeutics完成KT-621治疗特应性皮炎2B期Broaden2试验患者入组，关键数据预计2026年底公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1190555506","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190555506?lang=zh_cn&edition=full","pubTime":"2026-06-25 19:02","pubTimestamp":1782385353,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. 已顺利完成其候选药物KT-621用于治疗特应性皮炎的2B期Broaden2临床试验的患者入组工作。该试验的关键顶线数据预计将于2026年底前揭晓。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138193718","title":"Kymera Therapeutics宣布口服Irak4降解剂KT-485一期试验首例受试者给药，并达成与赛诺菲合作里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1138193718","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138193718?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:01","pubTimestamp":1781002892,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics公司宣布，其口服Irak4降解剂KT-485的一期临床试验已完成首例受试者给药。同时，该公司也确认已根据与赛诺菲（Sanofi）的合作协议，实现了一项重要的里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134368601","title":"Kymera Therapeutics 宣布在皮肤病研究学会和美国胸科学会大会上展示其首创口服Stat6降解剂KT-621","url":"https://stock-news.laohu8.com/highlight/detail?id=1134368601","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134368601?lang=zh_cn&edition=full","pubTime":"2026-05-15 19:01","pubTimestamp":1778842895,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. 宣布，其首创的口服STAT6降解剂KT-621的研究成果，将在即将举行的皮肤病研究学会和美国胸科学会国际大会上进行展示。该药物KT-621是一种旨在选择性降解STAT6蛋白的新型口服疗法。在SID和ATS这两个重要的学术会议上展示数据，意味着KT-621在皮肤病学和呼吸病学两个关键治疗领域均获得了研究进展的认可。对于Kymera公司而言，在权威学术会议上公布其领先项目的积极数据，是推动管线发展、增强投资者信心的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517437281","title":"Kymera Therapeutics, Inc.2024财年实现净利润-2.24亿美元，同比减少52.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517437281","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517437281?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363235,"startTime":"0","endTime":"0","summary":"3月8日，Kymera Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-2.24亿美元，同比减少52.38%；其中营业收入为47.07百万美元，同比减少40.11%，每股基本收益为-2.98美元。从资产负债表来看，Kymera Therapeutics, Inc.总负债1.42亿美元，其中短期债务13.11百万美元，资产负债比为6.89，流动比率为0.08。机构评级：截至2025年3月8日，当前有17家机构对Kymera Therapeutics, Inc.目标价做出预测，其中目标均价为58.82美元，其中最低目标价为41.00美元，最高目标价为97.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000043abed65dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000043abed65dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147904941","title":"异动解读 | Kymera Therapeutics第四季度业绩逊预期 盘中股价大跌7.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=1147904941","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147904941?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:10","pubTimestamp":1740669010,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics今日盘中股价大幅下跌7.27%,引发市场广泛关注。据统计,截至收盘KYMR报33.34美元,成交量3.18万股,振幅4.84%。公司最新公布的2024年第四季度财报显示,KYMR当季每股亏损0.88美元,远高于华尔街分析师预期的0.78美元亏损。与去年同期相比,营收更是大幅下滑84.56%。显而易见,Kymera Therapeutics业绩大幅逊于市场预期,给投资者带来了较大的不确定性和失望。公司财务数据的疲软表现,可能是导致KYMR股价今日大跌的主要诱因之一。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Kymera Therapeutics第四季度业绩逊预期 盘中股价大跌7.27%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385542","title":"Kymera Therapeutics, Inc.盘中异动 早盘大幅跳水5.71%报33.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385542","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514385542?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:40","pubTimestamp":1740667238,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时40分，Kymera Therapeutics, Inc.股票出现异动，股价大幅下跌5.71%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.69%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224039a2567cac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224039a2567cac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYMR","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121089825","title":"Kymera Therapeutics 2024年Q4 GAAP每股收益$(0.88)不及预期$(0.78)，销售额$739万不及预期$1182万","url":"https://stock-news.laohu8.com/highlight/detail?id=1121089825","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121089825?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:07","pubTimestamp":1740658067,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics报告季度每股亏损$，比分析师的共识预期$低12.82%。与去年同期每股亏损$相比，这是252%的下降。以上内容来自Benzinga Earnings专栏，原文如下：Kymera $Therapeutics$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 12.82 percent. This is a 252 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $7.39 million which missed the analyst consensus estimate of $11.82 million by 37.45 percent.  This is a 84.56 percent decrease over sale","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510803663","title":"Kymera Therapeutics, Inc.盘中异动 早盘快速下挫5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510803663","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510803663?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:41","pubTimestamp":1739284909,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时41分，Kymera Therapeutics, Inc.股票出现异动，股价大幅下挫5.13%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.30%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112241499881bf20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112241499881bf20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506585786","title":"Kymera Therapeutics, Inc.盘中异动 下午盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506585786","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506585786?lang=zh_cn&edition=full","pubTime":"2025-01-28 02:42","pubTimestamp":1738003369,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日02时42分，Kymera Therapeutics, Inc.股票出现异动，股价急速下跌5.03%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.81%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501280242499874d546&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501280242499874d546&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505427022","title":"Kymera Therapeutics, Inc.盘中异动 早盘股价大涨5.59%报42.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505427022","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505427022?lang=zh_cn&edition=full","pubTime":"2025-01-21 23:31","pubTimestamp":1737473477,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日23时31分，Kymera Therapeutics, Inc.股票出现异动，股价大幅拉升5.59%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.31%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121233117986e3ec5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121233117986e3ec5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504946517","title":"Kymera Therapeutics, Inc.盘中异动 急速跳水5.14%报41.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504946517","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504946517?lang=zh_cn&edition=full","pubTime":"2025-01-17 02:19","pubTimestamp":1737051560,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日02时19分，Kymera Therapeutics, Inc.股票出现异动，股价快速下跌5.14%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.36%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117021920abad80f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117021920abad80f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503642508","title":"Kymera Therapeutics, Inc.盘中异动 早盘大幅拉升5.18%报42.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503642508","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503642508?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:32","pubTimestamp":1736951530,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时32分，Kymera Therapeutics, Inc.股票出现异动，股价急速上涨5.18%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.77%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223210ababf25f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223210ababf25f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503572953","title":"Kymera Therapeutics, Inc.盘中异动 早盘股价大涨5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503572953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503572953?lang=zh_cn&edition=full","pubTime":"2025-01-14 23:06","pubTimestamp":1736867164,"startTime":"0","endTime":"0","summary":"北京时间2025年01月14日23时06分，Kymera Therapeutics, Inc.股票出现异动，股价快速上涨5.15%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114230604986609b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114230604986609b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503110589","title":"Kymera Therapeutics, Inc.盘中异动 早盘大幅跳水5.19%报36.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503110589","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503110589?lang=zh_cn&edition=full","pubTime":"2025-01-13 23:19","pubTimestamp":1736781593,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日23时19分，Kymera Therapeutics, Inc.股票出现异动，股价快速跳水5.19%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.16%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113231953a2204b76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113231953a2204b76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502860702","title":"Kymera Therapeutics, Inc.盘中异动 股价大跌5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502860702","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502860702?lang=zh_cn&edition=full","pubTime":"2025-01-10 23:00","pubTimestamp":1736521208,"startTime":"0","endTime":"0","summary":"北京时间2025年01月10日23时00分，Kymera Therapeutics, Inc.股票出现波动，股价大幅下跌5.28%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.83%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110230009a21d14ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110230009a21d14ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYMR","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kymeratx.com","stockEarnings":[{"period":"1week","weight":-0.0358},{"period":"1month","weight":-0.0822},{"period":"3month","weight":-0.0467},{"period":"6month","weight":0.2174},{"period":"1year","weight":0.8063},{"period":"ytd","weight":0.3889}],"compareEarnings":[{"period":"1week","weight":-0.0149},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.0243},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.1537},{"period":"ytd","weight":0.124}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kymera Therapeutics, Inc.是一家有限责任公司，于2017年5月25日根据特拉华州法律成立。该公司是一家生物制药公司，专注于发现和开发新型小分子疗法，利用人体自身的天然蛋白质降解系统选择性地降解致病蛋白。该公司拥有专有的靶向蛋白质降解平台，名为Pegasus，能够发现对全身致病蛋白具有强效活性的高选择性小分子蛋白质降解剂。该公司认为，其小分子蛋白质降解剂相比现有疗法具有显著优势，能够针对此前传统疗法难以触及的人类基因组的大部分区域进行治疗。该公司专注于已通过临床验证但关键生物节点/蛋白质尚未被药物靶向或药物靶向效果不佳的生物通路。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.060685},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.014692},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.075866},{"month":4,"riseRate":0.5,"avgChangeRate":0.006528},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.121889},{"month":6,"riseRate":0.666667,"avgChangeRate":0.163264},{"month":7,"riseRate":0.666667,"avgChangeRate":0.127227},{"month":8,"riseRate":0.666667,"avgChangeRate":0.054225},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.035696},{"month":10,"riseRate":0.571429,"avgChangeRate":0.0549},{"month":11,"riseRate":0.666667,"avgChangeRate":0.180891},{"month":12,"riseRate":0.666667,"avgChangeRate":0.094258}],"exchange":"NASDAQ","name":"Kymera Therapeutics, Inc.","nameEN":"Kymera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kymera Therapeutics, Inc.(KYMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kymera Therapeutics, Inc.,KYMR,Kymera Therapeutics, Inc.股票,Kymera Therapeutics, Inc.股票老虎,Kymera Therapeutics, Inc.股票老虎国际,Kymera Therapeutics, Inc.行情,Kymera Therapeutics, Inc.股票行情,Kymera Therapeutics, Inc.股价,Kymera Therapeutics, Inc.股市,Kymera Therapeutics, Inc.股票价格,Kymera Therapeutics, Inc.股票交易,Kymera Therapeutics, Inc.股票购买,Kymera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kymera Therapeutics, Inc.(KYMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}